A meta-analysis: association between Beta-2 adrenergic receptor Arg16Gly polymorphism and asthma in China

For different populations, the association studies between the beta-2 adrenergic receptor (ADRB2) Arg16Gly mutation and asthma are conflict. This study was designated to evaluate ADRB2 Arg16Gly polymorphism and asthma in Chinese population. Systemic assessment was performed based on the data from PubMed, Embase, Web of Science, the Cochrane Library, and Chinese National Knowledge Infrastructure (CNKI) up to January 2019. Odds ratios (ORs) with their 95% confidence intervals (95% CIs) were calculated using STATA software. This meta-analysis included 6143 asthma patients and 5919 healthy persons from 34 studies. Overall, ADRB2 Arg16Gly polymorphism showed no significant influence on asthma in China. However, subgroup analyses according to geographic areas, age group and HWE in controls, only found a borderline significant effect for southern Chinese under the homozygotes genetic model (OR = 0.82, 95%CI = 0.68-1.00, P = 0.046). This meta-analysis suggests that ADRB2 Arg16Gly polymorphism is not be related to the development of asthma in China.